Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

170919-Transgene-FPI-Announcement_US

Published 19 September 2017
Categorized as 2017, Press release, TG4001, TG4001

First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed

20170913 EN – CP Resultats financiers final

Published 13 September 2017
Categorized as 2017, Press release

Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)

Published 11 September 2017
Categorized as 2017, Press release, TG4010

Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress

20170907-ESMO-Metromajx-poster-EN

Published 7 September 2017
Categorized as 2017, Pexa-Vec, Press release

Transgene Announces Upcoming Investor Meetings

TNG-PR-financial-agenda-H217-EN

Published 31 August 2017
Categorized as 2017, Press release

First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

PR Pexa-Vec nivo EN

Published 31 July 2017
Categorized as 2017, Pexa-Vec, Press release

Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus

20170724 PR CancerResearch

Published 24 July 2017
Categorized as 2017, Press release

Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.

20170629 Servier Transgene EN

Published 29 June 2017
Categorized as 2017, Press release

Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris

20170622 CP RD Day EN

Published 22 June 2017
Categorized as 2017, Press release

Combined General Meeting of June 8, 2017

20170608 TG AGM June 2017 EN

Published 8 June 2017
Categorized as 2017, Press release

Posts pagination

Newer posts Page 1 … Page 27 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu